Literature DB >> 32029909

Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Tiago Nava1, Marc Ansari1, Jean-Hugues Dalle2, Christina Diaz de Heredia3, Tayfun Güngör4, Eugenia Trigoso5, Ulrike Falkenberg6, Alice Bertaina7, Brenda Gibson8, Andrea Jarisch9, Adriana Balduzzi10, Halvard Boenig11, Gergely Krivan12, Kim Vettenranta13, Toni Matic14, Jochen Buechner15, Krzysztof Kalwak16, Anita Lawitschka6, Akif Yesilipek17, Giovanna Lucchini18, Christina Peters6, Dominik Turkiewicz19, Riitta Niinimäki20, Tamara Diesch21, Thomas Lehrnbecher22, Petr Sedlacek23, Daphna Hutt24, Arnaud Dalissier25, Jacek Wachowiak26, Isaac Yaniv27, Jerry Stein27, Koray Yalçin28, Luisa Sisinni29, Marco Deiana30, Marianne Ifversen31, Michaela Kuhlen32, Roland Meisel33, Shahrzad Bakhtiar9, Simone Cesaro34, Andre Willasch9, Selim Corbacioglu35, Peter Bader36.   

Abstract

Hematopoietic stem cell transplantation (HSCT) is currently the standard of care for many malignant and nonmalignant blood diseases. As several treatment-emerging acute toxicities are expected, optimal supportive measurements critically affect HSCT outcomes. The paucity of good clinical studies in supportive practices gives rise to the establishment of heterogeneous guidelines across the different centers, which hampers direct clinical comparison in multicentric studies. Aiming to harmonize the supportive care provided during the pediatric HSCT in Europe, the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) promoted dedicated workshops during the years 2017 and 2018. The present paper describes the resulting consensus on the management of sinusoidal obstructive syndrome, mucositis, enteral and parenteral nutrition, iron overload, and emesis during HSCT.

Entities:  

Mesh：

Year:  2020        PMID： 32029909     DOI： 10.1038/s41409-020-0818-4

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  50 in total

1.  Veno-occlusive disease of the liver; essential pathology.

Authors:  G BRAS; K R HILL
Journal:  Lancet       Date:  1956-07-28       Impact factor: 79.321

Review 2.  Venous occlusive disease in children.

Authors:  Maged I Gharib; Sean R Bulley; John J Doyle; Robert F Wynn
Journal:  Thromb Res       Date:  2005-09-12       Impact factor: 3.944

3.  Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.

Authors:  Selim Corbacioglu; Simone Cesaro; Maura Faraci; Dominique Valteau-Couanet; Bernd Gruhn; Attilio Rovelli; Jaap J Boelens; Annette Hewitt; Johanna Schrum; Ansgar S Schulz; Ingo Müller; Jerry Stein; Robert Wynn; Johann Greil; Karl-Walter Sykora; Susanne Matthes-Martin; Monika Führer; Anne O'Meara; Jacek Toporski; Petr Sedlacek; Paul G Schlegel; Karoline Ehlert; Anders Fasth; Jacek Winiarski; Johan Arvidson; Christine Mauz-Körholz; Hulya Ozsahin; Andre Schrauder; Peter Bader; Joseph Massaro; Ralph D'Agostino; Margaret Hoyle; Massimo Iacobelli; Klaus-Michael Debatin; Christina Peters; Giorgio Dini
Journal:  Lancet       Date:  2012-02-23       Impact factor: 79.321

Review 4.  Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.

Authors:  Selim Corbacioglu; Elias J Jabbour; Mohamad Mohty
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-22       Impact factor: 5.742

5.  The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation.

Authors:  K Ohashi; J Tanabe; R Watanabe; T Tanaka; H Sakamaki; A Maruta; S Okamoto; N Aotsuka; K Saito; M Nishimura; H Oh; M Matsuzaki; S Takahashi; S Yonekura
Journal:  Am J Hematol       Date:  2000-05       Impact factor: 10.047

6.  A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.

Authors:  S H Park; M H Lee; H Lee; H S Kim; K Kim; W S Kim; C W Jung; Y H Im; S S Yoon; W K Kang; K Park; C H Park; S W Kim
Journal:  Bone Marrow Transplant       Date:  2002-01       Impact factor: 5.483

7.  Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial.

Authors:  J H Essell; M T Schroeder; G S Harman; R Halvorson; V Lew; N Callander; M Snyder; S K Lewis; J P Allerton; J M Thompson
Journal:  Ann Intern Med       Date:  1998-06-15       Impact factor: 25.391

8.  Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation.

Authors:  Tapani Ruutu; Britta Eriksson; Kari Remes; Eeva Juvonen; Liisa Volin; Mats Remberger; Terttu Parkkali; Hans Hägglund; Olle Ringdén
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

9.  Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.

Authors:  S Corbacioglu; E Carreras; M Ansari; A Balduzzi; S Cesaro; J-H Dalle; F Dignan; B Gibson; T Guengoer; B Gruhn; A Lankester; F Locatelli; A Pagliuca; C Peters; P G Richardson; A S Schulz; P Sedlacek; J Stein; K-W Sykora; J Toporski; E Trigoso; K Vetteranta; J Wachowiak; E Wallhult; R Wynn; I Yaniv; A Yesilipek; M Mohty; P Bader
Journal:  Bone Marrow Transplant       Date:  2017-07-31       Impact factor: 5.483

10.  Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.

Authors:  M Mohty; F Malard; M Abecassis; E Aerts; A S Alaskar; M Aljurf; M Arat; P Bader; F Baron; A Bazarbachi; D Blaise; F Ciceri; S Corbacioglu; J-H Dalle; F Dignan; T Fukuda; A Huynh; T Masszi; M Michallet; A Nagler; M NiChonghaile; S Okamoto; A Pagliuca; C Peters; F B Petersen; P G Richardson; T Ruutu; B N Savani; E Wallhult; I Yakoub-Agha; R F Duarte; E Carreras
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483
View more
  5 in total

Review 1.  Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia.

Authors:  Matthias Wölfl; Muna Qayed; Maria Isabel Benitez Carabante; Tomas Sykora; Halvard Bonig; Anita Lawitschka; Cristina Diaz-de-Heredia
Journal:  Front Pediatr       Date:  2022-01-06       Impact factor: 3.418

Review 2.  Cytomegalovirus in Haematological Tumours.

Authors:  Sara Alonso-Álvarez; Enrique Colado; Marco A Moro-García; Rebeca Alonso-Arias
Journal:  Front Immunol       Date:  2021-10-18       Impact factor: 7.561

3.  The Metabolic Impact of Two Different Parenteral Nutrition Lipid Emulsions in Children after Hematopoietic Stem Cell Transplantation: A Lipidomics Investigation.

Authors:  Oscar Daniel Rangel-Huerta; María José de la Torre-Aguilar; María Dolores Mesa; Katherine Flores-Rojas; Juan Luis Pérez-Navero; María Auxiliadora Baena-Gómez; Angel Gil; Mercedes Gil-Campos
Journal:  Int J Mol Sci       Date:  2022-03-27       Impact factor: 5.923

4.  Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation.

Authors:  Lilli Leimi; Kirsi Jahnukainen; Helena Olkinuora; Seppo Meri; Kim Vettenranta
Journal:  Bone Marrow Transplant       Date:  2022-02-17       Impact factor: 5.174

5.  Using the MDASI-Adolescent for Early Symptom Identification and Mitigation of Symptom Impact on Daily Living in Adolescent and Young Adult Stem Cell Transplant Patients.

Authors:  Irtiza N Sheikh; Jeffrey Miller; Basirat Shoberu; Clark R Andersen; Jian Wang; Loretta A Williams; Kris M Mahadeo; Rhonda Robert
Journal:  Children (Basel)       Date:  2021-12-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.